The ORAL Surveillance A3921133 study (NCT02092467), a regulatory agency-required open-label randomized controlled trial (RCT), compared the safety profiles of tofacitinib and TNF inhibitors for CV and malignancy risk in RA patients. Here, TNF is linked to rheumatoid arthritis.